Spica Healthcare — Unit of Grover Hospital, Bathinda
HomeHealth Guides & BlogsMedical Oncology & ChemotherapyProstate Cancer Castration Resistance: PSMA-Targeted Radioligand Therapy (177Lu-PSMA-617) and Next-Generation AR Blockers
Medical Oncology & Chemotherapy

Prostate Cancer Castration Resistance: PSMA-Targeted Radioligand Therapy (177Lu-PSMA-617) and Next-Generation AR Blockers

11 min read
Sep 4, 2026
Spica Healthcare Clinical & Surgical Protocol Illustration #106

Clinical Summary & Key Takeaways

A definitive oncological review on Metastatic Castration-Resistant Prostate Cancer (mCRPC), detailing PSA kinetics, second-generation androgen receptor axis-targeted therapies (Enzalutamide, Abiraterone), homologous recombination repair (HRR/BRCA) testing for PARP inhibitors, and Theranostic 177Lu-PSMA-617 therapy.

CRITICAL CLINICAL RED FLAG: Patients with prostate cancer on androgen deprivation therapy (ADT) who exhibit consecutive rising PSA levels (>2 ng/mL above nadir) or new persistent bone pain require urgent 68Ga-PSMA-11 PET-CT imaging to detect early castration-resistant metastasis.

1. The Evolution to Castration Resistance (mCRPC)

Despite initial suppression of serum testosterone (<50 ng/dL) with LHRH agonists, prostate cancer cells adapt through AR gene amplification, point mutations, and intracrine steroid synthesis, progressing to Castration-Resistant Prostate Cancer (CRPC).

  • PSA Velocity & Doubling Time: A doubling time of <6 months identifies high risk of rapid skeletal metastasis.

  • 68Ga-PSMA PET-CT: Unsurpassed sensitivity in detecting millimeter-sized pelvic nodal and bone marrow metastases.

  • Germline & Somatic HRR Gene Testing: Identifies BRCA1, BRCA2, ATM, and CDK12 mutations in up to 25% of mCRPC patients.

2. Second-Generation AR Pathway Inhibitors (ARPI)

Combining modern AR pathway inhibitors with continuous ADT extends overall survival by years:

  1. Enzalutamide / Apalutamide / Darolutamide: Potent androgen receptor antagonists that prevent AR nuclear translocation and DNA binding.

  2. Abiraterone Acetate + Prednisone: Selective CYP17 enzyme inhibitor blocking androgen biosynthesis in the testes, adrenals, and tumor tissue.

  3. PARP Inhibitors (Olaparib / Rucaparib): Induce synthetic lethality in HRR-mutated mCRPC, extending radiographic progression-free survival (PROfound trial).

"Theranostics embodies the pinnacle of precision oncology: if we can see the tumor on a diagnostic PSMA scan, we can deliver targeted beta-radiation directly to destroy the cancer cells from within." — Dr. Neha Gupta
Spica Healthcare Clinical & Surgical Protocol Illustration #106
Spica Healthcare Clinical & Surgical Protocol Illustration #106

3. 177Lutetium-PSMA-617: The VISION Trial Breakthrough

177Lu-PSMA-617 binds selectively to Prostate-Specific Membrane Antigen (PSMA) overexpressed on prostate carcinoma cells, delivering localized cytotoxic beta-radiation over a 1 to 2 mm radius while sparing healthy tissues.

CLINICAL CAUTION: PSMA-PET imaging must show high tumor PSMA avidity (SUVmax > 1.5x liver uptake) and absence of PSMA-negative discordant FDG-avid lesions to qualify for 177Lu-PSMA-617 radioligand therapy.

4. Bone Health & Preventing Skeletal-Related Events (SREs)

Mandatory co-administration of bone-targeting antiresorptive agents (Denosumab 120 mg subcutaneous q4w or Zoledronic Acid) with oral calcium and vitamin D prevents pathological fractures, cord compression, and severe bone pain.

5. Peer-Reviewed References & Clinical Guidelines

1. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION Trial) — NEJM, 2021; 385: 1091-1103.

2. Olaparib for Metastatic Castration-Resistant Prostate Cancer (PROfound Trial) — NEJM, 2020; 382: 2091-2102.

Frequently Asked Patient Questions

Yes. Over 85% of modern systemic cancer protocols are delivered safely in dedicated outpatient daycare infusion suites with continuous electronic vitals monitoring, allowing patients to sleep in their own beds at home the same night.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Senior Consultant & Clinical Director — Medical Oncology

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Share this medical guide:
WhatsApp
Director-Led Clinical Breakthroughs

Signature Surgical Innovations & Techniques

Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

1 of 13
Comprehensive Bone Cancer Oncology & Limb Preservation
Click to Watch Video Demonstration
95%+ Limb Salvage & MAP Chemotherapy
Multidisciplinary Limb Salvage, MAP Chemotherapy & Modular Megaprosthetics

Comprehensive Bone Cancer Oncology & Limb Preservation

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.

Key Advantages Over Conventional Surgery:
Coordinated Surgical & Medical Oncology: Seamless dual leadership under Dr. Deepak Garg & Dr. Neha Gupta
95%+ Limb Preservation Rate: Wide oncological bone resection avoiding traumatic limb amputations
High-Grade Sarcoma Chemotherapy: Standardized MAP and VIDE protocols delivering high tumor necrosis rates (>90%)
Custom Modular Megaprostheses: Immediate joint restoration with biological tendon ingrowth collars
Why Families & Physicians Trust Spica

World-Class Clinical Precision, Built on Compassion

Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.

AIIMS & Tata Memorial Alumni25+ Yrs Combined Senior Leadership

15,000+ Complex Surgeries & 100% Director-Led Evaluations

Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.

15,000+Surgeries Completed
95%+Limb Salvage Rate
<0.3%Infection Benchmark
Pre-Op 3D Virtual Planning 100% Direct Director OPD Day-1 Walking Protocol
Sub-Millimeter Accuracy

3D Navigated Robotics & Day-1 Walking

Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.

ROSA Robotics & Stryker Nav
Malwa Punjab Exclusive

Limb-Salvage Over Amputation

South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.

Modular Megaprosthesis
0-Out-Of-Pocket Options

100% Cashless PM-JAY & TPAs

Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.

Ayushman + 30+ TPAs Empanelled
24/7 Tertiary Ready

Class-100 Laminar Flow OTs & ICU

Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.

Spica Healthcare Bathinda
Expert Surgical Directors

Meet the Doctors at Spica Healthcare

Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Dr. Neha Gupta

Senior Consultant & Clinical Director — Medical Oncology

13+ Yrs Exp

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Medical Oncology & ChemotherapyImmunotherapy & Targeted OncologyPrecision Oncology & Cancer GenomicsPreventive Cancer ScreeningPalliative & Supportive OncologyHormonal TherapyComprehensive Cancer Treatments
Dr. Deepak Garg - Director & Senior Joint Replacement, Spine and Orthopaedic Oncologist

Dr. Deepak Garg

Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery

16+ Yrs Exp

MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)

Orthopaedic Oncology & Bone Tumors3D Robotic Joint ReplacementSports Injuries & ArthroscopyTrauma & Fracture ReconstructionGeneral Orthopaedics & Spine CareComprehensive Cancer Treatments
Community Health & Academic Outreach

Upcoming Health Camps & Academic Events

Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.

Curious what families & patients experience

Hear what our patients are saying

Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.

Health Knowledge & Clinical Guides

Doctor-Authored Health Guides

Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.